DE60032255D1 - Polymer-stabilisierte neuropeptide - Google Patents

Polymer-stabilisierte neuropeptide

Info

Publication number
DE60032255D1
DE60032255D1 DE60032255T DE60032255T DE60032255D1 DE 60032255 D1 DE60032255 D1 DE 60032255D1 DE 60032255 T DE60032255 T DE 60032255T DE 60032255 T DE60032255 T DE 60032255T DE 60032255 D1 DE60032255 D1 DE 60032255D1
Authority
DE
Germany
Prior art keywords
polymer
neuropeptides
stabilized
blood
passing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032255T
Other languages
English (en)
Other versions
DE60032255T2 (de
Inventor
David Bentley
James Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics AL Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics AL Corp filed Critical Nektar Therapeutics AL Corp
Application granted granted Critical
Publication of DE60032255D1 publication Critical patent/DE60032255D1/de
Publication of DE60032255T2 publication Critical patent/DE60032255T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60032255T 1999-10-04 2000-10-04 Polymer-stabilisierte neuropeptide Expired - Lifetime DE60032255T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15750399P 1999-10-04 1999-10-04
US157503P 1999-10-04
US16658999P 1999-11-19 1999-11-19
US166589P 1999-11-19
PCT/US2000/041070 WO2001024831A2 (en) 1999-10-04 2000-10-04 Polymer stabilized neuropeptides

Publications (2)

Publication Number Publication Date
DE60032255D1 true DE60032255D1 (de) 2007-01-18
DE60032255T2 DE60032255T2 (de) 2007-06-28

Family

ID=26854193

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032255T Expired - Lifetime DE60032255T2 (de) 1999-10-04 2000-10-04 Polymer-stabilisierte neuropeptide

Country Status (11)

Country Link
US (6) US20020019340A1 (de)
EP (1) EP1221975B1 (de)
JP (1) JP4027663B2 (de)
KR (1) KR100619612B1 (de)
AT (1) ATE347377T1 (de)
AU (1) AU782298B2 (de)
CA (1) CA2385533C (de)
DE (1) DE60032255T2 (de)
ES (1) ES2275561T3 (de)
MX (1) MXPA02003176A (de)
WO (1) WO2001024831A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
DE60032255T2 (de) * 1999-10-04 2007-06-28 Nektar Therapeutics Al, Corp., Huntsville Polymer-stabilisierte neuropeptide
EA006655B1 (ru) 2001-05-17 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
JP4838968B2 (ja) * 2001-09-28 2011-12-14 参天製薬株式会社 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
EP1978987B1 (de) 2006-01-05 2014-12-31 University of Utah Research Foundation Verfahren und zusammensetzungen in zusammenhang mit der verbesserung von eigenschaften pharmakologischer wirkstoffe für das nervensystem
PL381925A1 (pl) * 2007-03-07 2008-09-15 Andrzej W. Lipkowski Zastosowanie peptydu i przeciwbólowy środek farmaceutyczny
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US10540861B2 (en) * 2007-12-20 2020-01-21 Ncr Corporation Sustained authentication of a customer in a physical environment
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
EP2350118B1 (de) * 2008-09-19 2016-03-30 Nektar Therapeutics Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
US20110171165A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20120195847A1 (en) * 2008-09-19 2012-08-02 Nektar Therapeutics Polymer conjugates of biphalin peptides
DE202009004764U1 (de) * 2009-04-30 2010-09-16 Hettich Holding Gmbh & Co. Ohg Siphon und Möbel
JP5864556B2 (ja) 2010-05-27 2016-02-17 ヤンセン バイオテツク，インコーポレーテツド インスリン様成長因子１受容体結合ペプチド
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
CN103517712A (zh) * 2010-12-15 2014-01-15 神经佐剂股份有限公司 神经肽类似物、组合物和治疗疼痛的方法
EP2476410A1 (de) * 2011-01-13 2012-07-18 Theralpha Analgetische Peptid enthaltende Zusammensetzung zur transbuccalen Verabreichung
WO2012095523A1 (en) * 2011-01-13 2012-07-19 Theralpha Analgesic composition for transbuccal administration
WO2015152182A1 (ja) * 2014-03-31 2015-10-08 日油株式会社 環状ベンジリデンアセタールリンカーを有する親水性ポリマー誘導体
CN111220676B (zh) * 2019-11-13 2022-11-29 上海药明生物技术有限公司 利用毛细管电泳技术检测含聚乙二醇的蛋白质样品纯度的方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4468383A (en) * 1982-09-29 1984-08-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service Dimeric enkephalins
US4518711A (en) * 1983-05-16 1985-05-21 Gibson-Stephens Institute Conformationally constrained cyclic enkephalin analogs with delta receptor specificity
US4684624A (en) * 1983-12-22 1987-08-04 Yoshio Hosobuchi Method of treating cerebral ischemia
IT206701Z2 (it) * 1985-08-02 1987-10-01 Gate Spa Ventilatore assiale particolarmente per autoveicoli
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE164080T1 (de) * 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5326751A (en) * 1992-06-26 1994-07-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Enkephalin analogs
EP0599303A3 (de) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1995000162A1 (en) * 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US5945510A (en) 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
IL136680A0 (en) * 1997-12-12 2001-06-14 Macromed Inc Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
ES2242396T3 (es) * 1998-04-28 2005-11-01 Applied Research Systems Ars Holding N.V. Conjugados de analogos de peg-lhrh.
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
DE60032255T2 (de) 1999-10-04 2007-06-28 Nektar Therapeutics Al, Corp., Huntsville Polymer-stabilisierte neuropeptide
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
LT1436012T (lt) * 2001-10-18 2018-04-10 Nektar Therapeutics Opioidų antagonistų polimerų konjugatai

Also Published As

Publication number Publication date
WO2001024831A9 (en) 2002-11-14
DE60032255T2 (de) 2007-06-28
AU782298B2 (en) 2005-07-14
US20030139346A1 (en) 2003-07-24
KR100619612B1 (ko) 2006-09-01
EP1221975B1 (de) 2006-12-06
AU1631201A (en) 2001-05-10
JP2003511357A (ja) 2003-03-25
US20030144207A1 (en) 2003-07-31
ATE347377T1 (de) 2006-12-15
CA2385533A1 (en) 2001-04-12
CA2385533C (en) 2008-03-25
US8440623B2 (en) 2013-05-14
JP4027663B2 (ja) 2007-12-26
US20110257106A1 (en) 2011-10-20
US8008435B2 (en) 2011-08-30
US20020019340A1 (en) 2002-02-14
WO2001024831A2 (en) 2001-04-12
US20020013266A1 (en) 2002-01-31
WO2001024831A3 (en) 2002-03-07
KR20020032604A (ko) 2002-05-03
ES2275561T3 (es) 2007-06-16
US20040038899A1 (en) 2004-02-26
EP1221975A2 (de) 2002-07-17
MXPA02003176A (es) 2002-09-30

Similar Documents

Publication Publication Date Title
ATE347377T1 (de) Polymer-stabilisierte neuropeptide
CO5540371A2 (es) Administracion pulmonar de insulina quimicamente modificada
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
NO20023315D0 (no) G-CSF konjugater
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE359829T1 (de) Wasserlösliche polymerkonjugate von retinoesäure
YU56693A (sh) Konjugati peg-interferon
DE60006100D1 (de) Lang wirkende insulinotrope peptide
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
ATE287705T1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
PT1196443E (pt) Conjugados de eritropoietina com polietileno glicol
NO20024891D0 (no) Farmasöytiske sammensetninger
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
EA200300852A1 (ru) Конъюгаты нейбластина с полимерами и способы их применения
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
CY1108197T1 (el) Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv
ATE273684T1 (de) Eingekapselte wasserdispergierbare perfluoroetherpolymere
RU93057952A (ru) Биологический активный макромолекулярный конъюгат, гидразинсодержащие конъюгаты полипептидов и гликополипептидов с полимерами
YU29492A (sh) Konjugati proteina sa polietilenom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEKTAR THERAPEUTICS (N.D.GES.D. STAATES DELAWA, US